SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... -- Ignore unavailable to you. Want to Upgrade?


To: TATRADER who wrote (57538)2/12/2007 11:55:37 PM
From: Malyshek  Respond to of 59879
 
Thanks for the input!



To: TATRADER who wrote (57538)2/13/2007 7:52:28 AM
From: smahi  Respond to of 59879
 
Mark can you take a look at TELK,CBRX,ADLR&YMI



To: TATRADER who wrote (57538)2/13/2007 9:01:48 AM
From: hotlinktuna  Respond to of 59879
 
News out on CYCR .60 close: CytoCore, Inc. Establishes New Office in Bio-Pharma Hub
Tuesday February 13, 3:20 am ET
e2 Collector(TM) and Other Reproductive Cancer Screening and Treatment Tools Move Toward Distribution

PRINCETON, N.J.--(BUSINESS WIRE)--CytoCore, Inc. (OTCBB:CYCR - News), the late-stage bio-scientific research and medical device company for early reproductive cancer treatment, today announced the opening of its new office in this well-known hub for leading-edge solutions to women's health issues.
ADVERTISEMENT


"As our suite of early screening, diagnostic and treatment tools moves from the research to production stage, CytoCore wants to be poised to tap into the extensive concentration of capabilities in New Jersey's thriving bio-pharmaceutical business community," said Dr. Augusto Ocana, the Company's chief executive officer, who will be based in the new Princeton, N.J., office. "We're positioning ourselves for an optimal transition into the distribution phase for our endometrial, uterine and cervical cancer products."

Currently engaged in clinical trials for the FDA-approved e2 Collector sampling device, CytoCore expects to be in production by early summer. The new balloon sampling method -- the first significant upgrade to the Pap test in 50 years -- is designed to enhance the thoroughness and consistency of cell collections for the Pap smear and HPV test screenings performed annually on some 180 million women worldwide.

"We expect to be ready for volume production by mid-summer, producing up to 800,000 units a month on one shift," Dr. Ocana said. "Not only will we be offering a more cost-effective sample collection method, we're also improving the patient's comfort through our new, noninvasive collection procedure and the physician's confidence in the quality of that sample. We believe that our niche strategy will allow us to drive our products into the markets worldwide."

CytoCore's new office is located at:

212 Carnegie Center, Suite 206
Princeton, N.J. 08540
Telephone: 609.524.2570
Facsimile: 609.520.8731

For further information about the e2 Collector and CytoCore's full suite of products for the early screening, diagnoses and treatment of reproductive cancers, visit www.CytoCoreInc.com.

About CytoCore Inc.

CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com.

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.

Contact:
Communications & Business Development Consultant on
behalf of CytoCore, Inc.
Gene Martineau, 212-348-1880
ebm@interport.net
or
SIPR
Leslie McCarthy, 650-400-4547
Leslie@sipr.com

--------------------------------------------------------------------------------
Source: CytoCore, Inc.



To: TATRADER who wrote (57538)2/13/2007 9:41:35 AM
From: hotlinktuna  Respond to of 59879
 
Watch CYCR .62 +.02 now equal to 52wk high...breakout coming??! tuna



To: TATRADER who wrote (57538)2/13/2007 10:25:15 AM
From: hotlinktuna  Respond to of 59879
 
Added CSUH 3.14/3.30 calorie burning drink: Celsius(R), Earth's First Calorie Burning Soda, Named #1 Food and Beverage Trend for 2007 by Prestigious Market Research Firm Datamonitor
Tuesday February 13, 10:12 am ET

DELRAY BEACH, Fla., Feb. 13 /PRNewswire-FirstCall/ -- Celsius Holdings, Inc. (OTC Bulletin Board: CSUH.OB - News) announced today that Datamonitor, the world's leading provider of online data, analytic and forecasting platforms for key vertical sectors, named Celsius®, earth's first calorie burning soda, and the category of calorie burning beverages, as the number one food and beverage trend for 2007.
ADVERTISEMENT


(Photo: newscom.com )

In its Productscan Online new products database, Datamonitor found that Celsius® was helping to create a new niche of calorie burning beverages. The Datamonitor report said Celsius® was a "breakthrough beverage." Already being credited with being, "First to market," Datamonitor said, "New in the USA, Celsius® is billed as 'Earth's first calorie burning soda,' and uses green tea with EGCG, ginger, caffeine and other ingredients to raise metabolism to burn calories."

"Celsius created the calorie burning category for soft drinks and has rapidly gained a loyal following among consumers, retailers, and distributors. The fact that a highly respected analyst firm such as Datamonitor ranked this new category as the number one food and beverage trend for 2007 is a significant validation of the popularity of the benefits Celsius® offers," said Steve Haley, CEO of Celsius, Inc., the maker of Celsius®.

About Celsius

Celsius® has been clinically proven to burn calories, boost energy, and increase metabolism, on average 12% for up to 3 hours. Celsius® contains a healthy blend of ingredients including Green Tea with EGCG, Ginger, Calcium, Chromium, B Vitamins, and Vitamin C. Celsius® contains none of the bad ingredients typically found in soft drinks - no sugar, no carbs, no preservatives, no high fructose corn syrup, no trans fat, and it has very little sodium. Celsius® is a dietary supplement regulated by the FDA for food safety and quality manufacturing, and by the FTC for product packaging claims.

Celsius® is not a replacement for exercise and it is not a weight loss product; it is a replacement beverage for people who love the great taste of a soft drink and the energy of an energy drink, without the bad-for-you ingredients.

Celsius® has received many awards, accolades and broad recognition for its innovation and appeal to the consumer. Most recently, respected industry analysts DataMonitor ranked Celsius® and calorie burning beverages as the "Number One Food and Beverage Trend for 2007". Our recognition as Beverage Industry Magazine's "Best New Product - 2005", CSP Retailer's Choice "Finalist for Soft Drinks 2006." Celsius® has been featured on more than 725 television newscasts including the "NBC Today Show" with Matt Lauer.

Celsius® is available in 5 great tasting flavors including Orange, Cola, Lemon-Lime, Wild Berry and Ginger Ale. Each 12-ounce bottle of Celsius® retails for about $1.99. For more information and to view the Datamonitor press release, visit www.celsius.com.

About Celsius Holdings, Inc.

Celsius Holdings, Inc. (OTC Bulletin Board: CSUH.OB - News) manufactures Celsius® through its wholly-owned operating subsidiary, Celsius, Inc. Celsius Inc., a leader in the emerging $25 billion functional food and beverage category, is focused on the development and marketing of healthy, performance-based beverages. Celsius, Inc. is an innovative sports nutrition company dedicated to bringing consumers healthier refreshment through science and nutrition.

Forward-Looking Statements

This press release may contain statements, which are not historical facts and are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements contain projections of Celsius Holdings' future results of operations, financial position or state other forward-looking information. In some cases you can identify these statements by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "will," and "would" or similar words. You should not rely on forward-looking statements because Celsius Holdings' actual results may differ materially from those indicated by these forward-looking statements as a result of a number of important factors. These factors include, but are not limited to: general economic and business conditions; our business strategy for expanding our presence in our industry; anticipated trends in our financial condition and results of operation; the impact of competition and technology change; existing and future regulations effecting our business, and other risks and uncertainties discussed under the heading "Description of Business - Risk Factors" in Celsius Holdings' report on Form 8-K as filed with the Securities and Exchange Commission on February 2, 2007, and other reports Celsius Holdings files from time to time with the Securities and Exchange Commission. Celsius Holdings does not intend to and undertakes no duty to update the information contained in this press release.

--------------------------------------------------------------------------------
Source: Celsius Holdings, Inc.



To: TATRADER who wrote (57538)2/13/2007 3:56:05 PM
From: hotlinktuna  Respond to of 59879
 
New coverage on DRGV .041 here: Equity Stock Analysis Initiates Research Coverage of Dragon Capital Group Corporation with a Rating of ''Attractive''
Tuesday February 13, 10:39 am ET

DALLAS--(BUSINESS WIRE)--Equity Stock Analysis today announced that it has initiated coverage of Dragon Capital Group Corporation (OTC:DRGV - News) with a rating of "Attractive" by Equity Stock Analysis (ESA). The report is authored by Senior Research Analyst, Kris Gupta, CFA.
ADVERTISEMENT


The full report is available at equitystockanalysis.com.

In the report Chris Gupta indicates, "Dragon Capital Investment, Inc. offers early stage investment in China. Dragon with its long-term relations in China has been able to choose which early stage China-based companies will be able to capitalize on domestic and international markets while executing a growth strategy.

"By numbers alone, China's size and growth is massive. China has 160 cities that are each home to populations in excess of 1 million, while the United States has just nine of that size. In 1990, China's share of world exports was almost 2%, yet by 2003 that number had expanded to 6 percent.

"China's manufacturing sector employs close to 100 million workers, in contrast to 14 million in the United States, according to the AFL-CIO. Moreover, according to the International Monetary Fund, China accounts for 29% of world trade in bicycles, 28% in toys, 25% in footwear and 20% in ready-made garments.

"China's national gross domestic product increased from 0.57% in 1989 to 20.46% last year-indicating that the startup market is producing vibrant companies with strong growth stories.

"Dragon Capital Investment, Inc. allows investors to pick the right partner for investment in China, someone who knows the territory. What Dragon knows best, as an early stage investor, is their own market and they are providing investors the opportunity to share in their foresight, experience and knowledge."

About Equity Stock Analysis

EQUITY STOCK ANALYSIS ("ESA") is committed to the highest ethical standards and as such is not subject to external pressure that is sometimes experienced to issue biased research. This pressure is avoided by refusing to accept companies that cannot be recommended with objectivity, quality, and accuracy of research. ESA and its Certified Financial Analysts are independent, objective, and have a reasonable and adequate basis for our investment recommendations. ESA has established formal written policies supporting independent and objective analyst research. ESA has senior corporate officer publicly attest, at least annually, to adherence to the policy.

Disclosure: Pentony Enterprises LLC was compensated for 500,000 free trading shares from a non controlling third party profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this. In accordance with our Equity Stock Analysis published Code of Ethics for Pink Sheet companies, Pentony Enterprises holds no shares upon the publication of this report.

Contact:
Dragon Capital Group Corp.
Richard Galterio, 1-877-China-57
info@dragoncapital.us
or
EquityStockAnalysis.com
Lee Anderson, Publisher, 214-458-4258
info@equitystockanalysis.com

--------------------------------------------------------------------------------
Source: Dragon Capital Group Corp.
Stock getting a lot of good news but little movement...tuna